olivLaw · US equity research
Design Therapeutics, Inc. DSGN
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
Design Therapeutics is a clinical-stage biopharmaceutical company developing GeneTAC® small molecules meant to address the underlying cause of inherited nucleotide repeat expansion diseases such as Friedreich ataxia. The company has no approved products and no product revenue, and it posted a net loss of 69.8 million USD in 2025, while early clinical results could shape its next steps.
At the close of 02 Nov 2026, Design Therapeutics, Inc. (DSGN) stock was 10.15 USD (−4.96% on the day), with market capitalisation 635.2 m USD, beta 1.23, 52-week range 6.24–15.94 USD. Latest reported quarter (Q2 2026): revenue of 0 USD, net income of -20.2 m USD, diluted EPS -0.32 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 37.7
- weak (30–45)
- Bollinger (20, 2)
- 9.56 – 11.96
- in the lower half of the band · %B 0.25 · band width 22.3%
- SMA 50 / 200
- 12.61 / 12.14
- mixed trend
- MACD (12, 26, 9)
- -0.52 / -0.62
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −17.7% | −2.3% | −15.4 pp | — |
| 3 months | −20.5% | −0.8% | −19.7 pp | — |
| 6 months | −22.9% | +4.7% | −27.7 pp | — |
| Year to date | +8.2% | +10.2% | −2.0 pp | — |
| 1 year | +51.5% | +10.3% | +41.2 pp | +7.6% |
| 3 years | +363.5% | +73.0% | +290.4 pp | +21.3% |
| 5 years | −39.6% | +61.8% | −101.4 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 ≈ | 0 ≈ | 0 | 0 | 0 ≈ |
| Research & development | 11.9 m | 12.2 m | 15.4 m | 15.7 m | 14.6 m | 13.4 m | 14.4 m | 16.4 m |
| Operating income | -16.2 m | -16.7 m | -20.4 m | -21.6 m | -19.3 m | -18.2 m | -19.7 m | -22.2 m |
| Net income | -13.0 m | -13.7 m | -17.7 m | -19.1 m | -17.0 m | -16.0 m | -17.6 m | -20.2 m |
| Diluted EPS | -0.23 | -0.24 ≈ | -0.31 | -0.34 | -0.30 | -0.27 ≈ | -0.29 | -0.32 |
| Operating cash flow | -9.5 m ≈ | -9.9 m | -16.8 m | -14.4 m ≈ | -11.2 m ≈ | -12.0 m | -16.4 m | -15.5 m ≈ |
| Capex | -16.0 k ≈ | 0 | 72.0 k | 87.0 k ≈ | 0 ≈ | 34.0 k | 0 | 21.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 226.0 k | unavailable | unavailable | unavailable | 0 | 0 |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Net income | -8.3 m | -35.5 m | -63.3 m | -66.9 m | -49.6 m | -69.8 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | -0.77 | -1.14 | -1.19 | -0.88 | -1.22 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -3,663.7% | unavailable | unavailable | unavailable | unavailable | unavailable |
| Free cash flow | -8.7 m | -30.9 m | -52.2 m | -58.8 m | -43.4 m | -54.6 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 16.9 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 212.5 m USD
- Total assets
- 226.2 m USD
- Debt / equity
- unavailable
- Current ratio
- 17.14x
- ROE
- -30.7%
- ROA
- -29.2%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 226.0 k | — | — | — | 0 | 0 | SEC (XBRL)· 09 Mar 2026verified |
| Research & development | 6.1 m | 24.8 m | 48.6 m | 57.1 m | 44.4 m | 59.1 m | SEC (XBRL)· 09 Mar 2026verified |
| Operating income | -8.3 m | -35.8 m | -67.6 m | -78.2 m | -62.4 m | -79.5 m | SEC (XBRL)· 09 Mar 2026verified |
| Income tax | — | — | — | — | 0 | 0 | SEC (XBRL)· 09 Mar 2026verified |
| Net income | -8.3 m | -35.5 m | -63.3 m | -66.9 m | -49.6 m | -69.8 m | SEC (XBRL)· 09 Mar 2026verified |
| Diluted EPS | — | -0.77 | -1.14 | -1.19 | -0.88 | -1.22 | SEC (XBRL)· 09 Mar 2026verified |
| Weighted average diluted shares | — | 45.9 m | 55.7 m | 56.0 m | 56.6 m | 57.3 m | SEC (XBRL)· 09 Mar 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 2.4 m | 298.6 m | 26.5 m | 21.2 m | 22.6 m | 16.9 m | SEC (XBRL)· 09 Mar 2026verified |
| Current assets | 36.2 m | 385.4 m | 335.1 m | 284.6 m | 248.0 m | 223.8 m | SEC (XBRL)· 09 Mar 2026verified |
| Property, plant & equipment, net | 71.0 k | 1.5 m | 1.9 m | 1.7 m | 1.4 m | 981.0 k | SEC (XBRL)· 09 Mar 2026verified |
| Total assets | 36.5 m | 390.6 m | 341.1 m | 289.6 m | 252.1 m | 226.2 m | SEC (XBRL)· 09 Mar 2026verified |
| Accounts payable | 1.4 m | 1.6 m | 3.0 m | 1.9 m | 2.2 m | 2.3 m | SEC (XBRL)· 09 Mar 2026verified |
| Current liabilities | 2.3 m | 5.3 m | 10.8 m | 9.6 m | 8.5 m | 13.1 m | SEC (XBRL)· 09 Mar 2026verified |
| Total liabilities | 2.5 m | 8.4 m | 13.8 m | 12.0 m | 10.0 m | 13.7 m | SEC (XBRL)· 09 Mar 2026verified |
| Equity | -11.3 m † | 382.1 m † | 327.3 m † | 277.7 m † | 242.1 m † | 212.5 m † | SEC (XBRL)· 09 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -8.7 m | -29.4 m | -51.3 m | -58.6 m | -43.1 m | -54.4 m | SEC (XBRL)· 09 Mar 2026verified |
| Capex | 76.0 k | 1.5 m | 918.0 k | 256.0 k | 340.0 k | 193.0 k | SEC (XBRL)· 09 Mar 2026verified |
| Free cash flow | -8.7 m ≈ | -30.9 m ≈ | -52.2 m ≈ | -58.8 m ≈ | -43.4 m ≈ | -54.6 m ≈ | SEC (XBRL)· 09 Mar 2026derived |
| Investing cash flow | -33.6 m | -53.6 m | -221.0 m | 52.5 m | 44.0 m | 22.9 m | SEC (XBRL)· 09 Mar 2026verified |
| Financing cash flow | 44.5 m | 379.2 m | 235.0 k | 724.0 k | 513.0 k | 25.7 m | SEC (XBRL)· 09 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 2 of at least 6
- score weight coverage: 12.5% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
02 Nov 2026Source: olivLaw, closing series
Market cap: 635.2 m USD
Key indicators
Coverage and freshness
Score by group
13% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 18.9x | 100 (on a fixed band) | 33% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -8.7% | 0 (on a fixed band) | 67% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Design Therapeutics, Inc. (DSGN). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 0 USD in 2025; ROE -34.1%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 18.9x
What contradicts it
- FCF yield: -8.7%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,327.4 bn | 45.8 | 86.1% | 31.9% | +44.7% | +31% / +139% |
| JNJJohnson & Johnson | 651.3 bn | 41.0 | 20.0% | 16.2% | +6.0% | +31% / +75% |
| ONCBeone Medicines Ltd. | 534.0 bn | 831.9 | 14.7% | 10.7% | +40.2% | +6% / +93% |
| ABBVAbbVie Inc. | 510.4 bn | 81.6 | — | 9.8% | +8.6% | +27% / +103% |
| MRKMerck & Co., Inc. | 366.0 bn | 118.5 | 7.0% | 4.8% | +1.3% | +42% / +45% |
| ABTAbbott Laboratories | 191.9 bn | 30.8 | 12.4% | 13.9% | +5.7% | −15% / +6% |
| PFEPfizer Inc | 174.8 bn | 40.3 | 5.0% | 6.8% | −1.6% | +19% / +1% |
| VRTXVertex Pharmaceuticals Inc | 140.2 bn | 32.2 | 23.5% | 35.0% | +8.9% | +28% / +56% |
| BMYBristol-Myers Squibb Company | 128.8 bn | 14.0 | 44.1% | 18.5% | −0.2% | +28% / +28% |
| TEVATeva Pharmaceutical Industries Limited | 47.4 bn | 67.9 | 9.7% | 5.0% | +4.3% | +51% / +314% |
| ZTSZoetis Inc. | 34.4 bn | 13.7 | 64.4% | 27.5% | +2.3% | −35% / −53% |
| ROIVRoivant Sciences Ltd. | 25.9 bn | — | -6.2% | -3,535.0% | −71.6% | +72% / +275% |
| RPRXRoyalty Pharma plc | 25.8 bn | 37.7 | 8.5% | 32.1% | +5.1% | +66% / +146% |
| UTHRUnited Therapeutics Corporation | 25.6 bn | 21.3 | 19.3% | 41.6% | +10.6% | +23% / +148% |
| INSMInsmed Inc | 24.0 bn | — | -72.5% | -39.9% | +66.7% | −47% / +337% |
| VTRSViatris Inc. | 21.4 bn | — | -23.6% | -23.9% | −3.0% | +75% / +103% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.2 bn | 8.0 | 126.6% | 52.8% | +65.2% | −65% / −6% |
| AXSMAxsome Therapeutics, Inc. | 7.2 bn | — | -175.6% | -18.2% | +65.5% | −10% / +102% |
| SNDXSyndax Pharmaceuticals, Inc. | 1.2 bn | — | -426.4% | -72.3% | +627.8% | −34% / −21% |
| JANXJanux Therapeutics, Inc. | 1.1 bn | — | -10.7% | -427.5% | −5.6% | −49% / +100% |
| KURAKura Oncology, Inc. | 870.9 m | — | -167.7% | -384.3% | +25.2% | −19% / +1% |
| DSGNDesign Therapeutics, Inc. | 635.2 m | — | -34.1% | — | unavailable | +51% / +363% |
| DMACDiaMedica Therapeutics Inc. | 501.0 m | — | -114.6% | — | unavailable | +8% / +281% |
| OVIDOvid Therapeutics Inc. | 466.8 m | — | -26.0% | -2,178.9% | +1,181.3% | +34% / −20% |
| ASMBAssembly Biosciences, Inc. | 397.2 m | — | -0.0% | -0.1% | +153.5% | −48% / +132% |
1- and 3-year price returns: for DSGN from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Design Therapeutics is a clinical-stage biopharmaceutical company developing GeneTAC® small molecules meant to address the underlying cause of inherited nucleotide repeat expansion diseases such as Friedreich ataxia. The company has no approved products and no product revenue, and it posted a net loss of 69.8 million USD in 2025, while early clinical results could shape its next steps.
SWOT
Strengths
- The GeneTAC® platform is proprietary and targets the genetic cause of several diseases. The company has reported positive early clinical-stage data and has a financial position that allows it to continue operations under the current plan.
- Programs are diversified across several rare diseases, which reduces dependence on a single clinical outcome. The company has received regulatory clearances for several clinical studies.
- A biomarker-driven strategy allows faster measurement of molecular activity, which could accelerate decisions on doses and next steps.
Weaknesses
- The company has no approved products and no product sales revenue, and net losses keep growing as studies advance.
- Cash reserves do not cover the full development path to approval, making additional capital necessary in the future.
- The company has limited experience running clinical trials and interacting with regulators, which could slow the planned timeline.
Opportunities
- If RESTORE-FA data hold at 12 weeks, the company could prepare a registration plan for Friedreich ataxia, a market with unmet needs.
- Partnerships or licences could bring funding and external validation, easing pressure on equity capital.
- Extending the GeneTAC® platform to other nucleotide repeat diseases could create new programs if preclinical research succeeds.
Threats
- Early clinical results can be revised by new data, and the failure of one program could affect investor confidence and the timeline of other studies.
- Delays in drug supply or patient recruitment, as happened in FECD, could postpone expected data.
- If financing is not available on acceptable terms, the company could be forced to reduce or stop some programs.
Risks
- Continuing net losseshigh
The company has posted net losses every year since inception and expects losses to increase in the coming years. If it does not become profitable, the company's value and financing capacity could be affected.
- Need for additional financinghigh
Existing funds are not enough to finance all programs through approval. If financing is not available in time, the company could delay or reduce development activities.
- Early clinical data and uncertaintyhigh
The programs are at early stages, and the company acknowledges it cannot be certain that studies will be completed on time or accepted by authorities. Early positive results do not guarantee success in later studies.
- Regulatory riskmedium
Authorities can impose suspensions or additional requirements, as happened with the DT-216P2 IND. Such measures could extend timelines and increase costs.
Investment thesis
What would need to be true (bull case)
- Early RESTORE-FA data showed frataxin increases and clinical improvements, which could support the idea that the genetic approach works in patients.
- The GeneTAC® platform applies to several rare diseases, and success in one program could validate the technology for the others.
- The company has kept up operational execution, with new steps in DM1 and changes to the RESTORE-FA study, showing an ability to respond to data.
What would break the thesis
- The company has no approved product and keeps posting losses, so its value depends heavily on future study outcomes.
- Additional financing could come with significant dilution or with the surrender of technology rights, which could reduce the benefit to shareholders.
- Recent delays, such as those in the FECD program and the changes to the RESTORE-FA study, show that timelines can slip, and expected data could be postponed again.
What to watch
- Update on DT-216P2 registrational plansQ4 2026
- RESTORE-FA data after 12 weeks of treatmentQ1 2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Design Therapeutics develops a new class of small molecules, called GeneTAC®, designed to target selectively the repeated sequences of defective genes and to modulate gene expression, either by increasing transcription or by reducing toxic gene products. The company focuses on diseases such as Friedreich ataxia, myotonic dystrophy type-1, Fuchs endothelial corneal dystrophy and Huntington's disease. It has no product approved for sale and has funded its activity through stock sales, convertible notes and grant revenue.
The company states that its capital needs are substantial and that existing funds, sufficient for more than 12 months under the current plan, will not be enough to fund all products through regulatory approval. To close that gap, Design could raise funds through equity, debt or collaborations, which could dilute existing shareholders.
Segments
Friedreich ataxia (DT-216P2)
The most advanced program targets Friedreich ataxia, a rare disease caused by low levels of frataxin. In May 2026, after four weeks of treatment at the 1 mpk dose, increases in frataxin and clinical improvements were reported; the company is modifying the RESTORE-FA study and expects 12-week data in the first quarter of 2027.
Market context
The company targets rare diseases with unmet medical needs, for which no approved treatments address the cause. Friedreich ataxia has an estimated prevalence of 1 in 40,000-50,000, with more than 5,000 individuals in the United States and more than 20,000 in Europe. The market for disease-modifying treatments remains largely unaddressed, which could offer opportunities if clinical data support efficacy.
Trends
- Interest in genetic therapies based on small moleculestailwind
The company works in the area of therapies that address the genetic cause of disease directly. If the GeneTAC® platform shows efficacy across several diseases, it could attract investor and industry partner attention.
- High capital requirements for clinical developmentheadwind
Advancing drugs through clinical phases requires large investment, and the company says it will need additional funding. This is a constant pressure on the capital structure and on dilution.
- Regulatory oversight and clinical holdsmixed
The US regulator placed a clinical hold on the DT-216P2 IND in June 2025, lifted in December 2025. Such events show that regulation can change timelines, although the clearance to continue studies offers support.
- Appetite for biotech partnershipsmixed
The company notes it could enter collaborations or licences for funding, which could ease financial pressure but could also involve giving up rights to technologies or products.
Competitive position
The company states that there are currently no approved therapeutic options that address the cause of nucleotide repeat expansion diseases. Competition may still come from therapies that treat symptoms or from other genetic approaches, and the sources reviewed do not identify all direct competitors.
In Fuchs dystrophy, direct competition is limited by the lack of approved disease-modifying treatments, and corneal surgery remains the only procedure. The company notes that biomarker-driven therapies are still few, which raises the risk of its development strategy.
- Symptomatic therapies for Friedreich ataxia
The sources state that no approved therapies address the cause of the disease; competition may centre on treatments that manage symptoms, without named companies in the sources reviewed.
- Corneal surgery for Fuchs dystrophy
It is the only approved procedure for restoring vision in Fuchs endothelial corneal dystrophy, making it a relevant alternative for patients.
- Other developers of small-molecule genetic therapies
The sources do not name other companies, but they imply that parallel research in genomic medicine exists.
- Therapies for myotonic dystrophy in development
The sources name no competitors, but the company states that no treatments address the cause of the disease, leaving room for other interventions.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report03 Aug 2026
- Current report03 Aug 2026Results of operations · Financial statements and exhibits
- Current report11 Jun 2026Shareholder vote
- Current report18 May 2026Other events
- Quarterly report28 Apr 2026
- Current report28 Apr 2026Results of operations · Regulation FD disclosure
- Proxy statement23 Apr 2026
- Current report01 Apr 2026Departure or appointment of officers
- Annual report09 Mar 2026
- Current report09 Mar 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Design Therapeutics, Inc. · 09 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Design Therapeutics, Inc. · 03 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Design Therapeutics, Inc. · 03 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.